Cargando…
Comparative assessment of therapeutic safety of norcantharidin, N-farnesyloxy-norcantharimide, and N-farnesyl-norcantharimide against Jurkat T cells relative to human normal lymphoblast: A quantitative pilot study
The therapeutic safety of an anticancer drug is one of the most important concerns of the physician treating the cancer patient. Half maximal inhibitory concentration (IC(50)) and hillslope are usually used to represent the strength and sensitivity of an anticancer drug on cancer cells. The therapeu...
Autores principales: | Chang, Ming-Che, Wu, Jin-Yi, Liao, Hui-Fen, Chen, Yu-Jen, Kuo, Cheng-Deng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979836/ https://www.ncbi.nlm.nih.gov/pubmed/27495082 http://dx.doi.org/10.1097/MD.0000000000004467 |
Ejemplares similares
-
N-Farnesyloxy-norcantharimide inhibits progression of human leukemic Jurkat T cells through regulation of mitogen-activated protein kinase and interleukin-2 production
por: Chang, Ming-Che, et al.
Publicado: (2015) -
Synthesis of Novel Lipophilic N-Substituted Norcantharimide Derivatives and Evaluation of Their Anticancer Activities
por: Wu, Jin-Yi, et al.
Publicado: (2014) -
The clinical efficacy and safety of vancomycin loading dose: A systematic review and meta-analysis
por: Mei, Hekun, et al.
Publicado: (2019) -
Safety profiles and adverse reactions of azithromycin in the treatment of pediatric respiratory diseases: A systematic review and meta-analysis
por: Sun, Ying-wen, et al.
Publicado: (2023) -
The potential mechanism of the Ruhao Dashi formula in treating acute pneumonia via network pharmacology and molecular docking
por: Yi, Xiu-Xiu, et al.
Publicado: (2023)